PamGene's microarray diagnostics shows promise:
This article was originally published in Clinica
PamGene International, of `s-Hertogenbosch, the Netherlands, says that preliminary results from research to develop rapid microarray diagnostics for tuberculosis identification and drug resistance monitoring are promising. The firm is developing the microarray platform, PamChip, with KIT Biomedical Research, the business unit of KIT at Amsterdam's Royal Tropical Institute. It claims that according to its research, the technology could represent the "world's fastest microarray". The rapid technology, it says, was achieved by pulsing the target through a porous substrate of different probes for mycobacteria species identification.